NCT06669117 - FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

October 21, 2030

Study Completion Date

October 1, 2032

Conditions

Solid TumorMET Alteration

Interventions

DRUG

VERT-002

Route of Administration: Intravenous

Trial Locations (19)

110

RECRUITING

Taipei Medical University Hospital, Taipei

1070

RECRUITING

Institut Jules Bordet, Anderlecht

1307

RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

10043

RECRUITING

Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

13915

RECRUITING

APHP de Marseille - Hôpital Nord, Marseille

20007

RECRUITING

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

31100

RECRUITING

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse

37203

RECRUITING

Sarah Cannon Research Institute Oncology Partners, Nashville

44718

RECRUITING

Gabrail Cancer Research Center, Canton

44805

RECRUITING

Institut de Cancerologie de Ouest (ICO) - Saint-Herblain, Saint-Herblain

45147

RECRUITING

Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO), Cologne

94805

RECRUITING

Gustave Roussy, Villejuif

100225

RECRUITING

National Taiwan University Hospital, Taipei

1066 CX

RECRUITING

Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

03722

RECRUITING

Yonsei University College of Medicine, Seoul

05505

RECRUITING

Asan Medical Center (AMC), Seoul

All Listed Sponsors

lead

Pierre Fabre Medicament

INDUSTRY